Synairgen (SNG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

4.63p
   
  • Change Today:
      0.040p
  • 52 Week High: 9.80p
  • 52 Week Low: 3.40p
  • Currency: UK Pounds
  • Shares Issued: 202.66m
  • Volume: 27,287
  • Market Cap: £9.38m
  • RiskGrade: 510
  • Beta: 1.51

Synairgen Overview

In the 1970s, Synairgen founder, British immunophysician Professor Sir Stephen Holgate, began investigating how respiratory viruses can cause serious illness, with the aim of translating these insights into effective clinical treatments. Joined by fellow University of Southampton professors Donna Davies and Ratko Djukanovic in the 1990s, together the three formed Synairgen in 2003 with the sole aim of bringing these advances to patients.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 0.7  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Synairgen Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 n/a (4.79) (3.53)p n/a n/a n/a n/a 0.0%
31-Dec-20 n/a (17.73) (9.46)p n/a n/a n/a n/a 0.0%
31-Dec-21 n/a (57.86) (24.28)p n/a n/a n/a n/a 0.0%
31-Dec-22 n/a (20.09) (8.76)p n/a n/a n/a n/a 0.0%
31-Dec-23 n/a (9.66) (4.18)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Synairgen Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-24 n/a (7.00) (2.98)p n/a n/a n/a n/a 0.0%
31-Dec-25 n/a (4.00) (1.49)p n/a n/a n/a n/a 0.0%

Copyright © 2024 FactSet Research Systems Inc. All rights reserved.

Synairgen Company Announcements

Exercise of Share Options and Total Voting Rights 30-Oct-2024 18:09 RNS
Results of AGM and Appointment of New Chairman 10-Oct-2024 17:05 RNS
Interim Results 26-Sep-2024 07:00 RNS

Synairgen ShareCast News

Synairgen names Joseph Colliver as CFO 11-Oct-2023 ShareCast
Synairgen posts positive results for phase 2 tri... 04-Oct-2022 ShareCast
Synairgen unveils positive clinical trial data 07-Sep-2022 ShareCast

Synairgen Top Newspaper Links

AstraZeneca buys the rights to an asthma treatme... 13-Jun-2014 Daily Mail
AstraZeneca in new £138million asthma drug deal 13-Jun-2014 Express & Star

Latest Synairgen Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Synairgen Market Data

Currency UK Pounds
Share Price 4.63p
Change Today 0.040p
% Change 0.87 %
52 Week High 9.80p
52 Week Low 3.40p
Volume 27,287
Shares Issued 202.66m
Market Cap £9.38m
Beta 1.51
RiskGrade 510

Synairgen Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
52.77% above the market average52.77% above the market average52.77% above the market average52.77% above the market average52.77% above the market average
80.00% above the sector average80.00% above the sector average80.00% above the sector average80.00% above the sector average80.00% above the sector average
Price Trend
79.28% below the market average79.28% below the market average79.28% below the market average79.28% below the market average79.28% below the market average
63.27% below the sector average63.27% below the sector average63.27% below the sector average63.27% below the sector average63.27% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 0
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 1
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Synairgen Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
15:53 46 @ 4.92p
15:35 3,129 @ 4.40p
15:09 4,000 @ 4.40p
13:55 2,503 @ 4.72p
13:03 8,609 @ 4.40p

Synairgen Key Personnel

CEO Richard J Marsden

Top of Page